MGO One Seven LLC Raises Stake in Sanofi (NASDAQ:SNY)

MGO One Seven LLC increased its holdings in Sanofi (NASDAQ:SNY - Free Report) by 125.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,408 shares of the company's stock after purchasing an additional 13,022 shares during the quarter. MGO One Seven LLC's holdings in Sanofi were worth $1,129,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Hsbc Holdings PLC increased its stake in Sanofi by 258.6% during the fourth quarter. Hsbc Holdings PLC now owns 35,033 shares of the company's stock worth $1,695,000 after acquiring an additional 25,263 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Sanofi by 33.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,174 shares of the company's stock valued at $153,000 after purchasing an additional 792 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in shares of Sanofi by 7.2% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 409,290 shares of the company's stock worth $19,740,000 after purchasing an additional 27,330 shares during the last quarter. Finally, MML Investors Services LLC boosted its stake in Sanofi by 4.7% during the fourth quarter. MML Investors Services LLC now owns 241,401 shares of the company's stock worth $11,643,000 after buying an additional 10,865 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Down 1.2 %

Shares of SNY stock traded down $0.66 during trading hours on Thursday, reaching $54.30. 479,346 shares of the stock were exchanged, compared to its average volume of 2,345,984. The business's fifty day moving average is $54.51 and its two-hundred day moving average is $52.07. The firm has a market capitalization of $137.16 billion, a P/E ratio of 21.81, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The company's revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.78 EPS. As a group, research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. Sanofi's payout ratio is presently 57.14%.

Analysts Set New Price Targets

Several research firms recently weighed in on SNY. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.